Clinical trials
Leukemia, Myeloid, Acute trials in Finland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2008 | 1 |
| 2013 | 2 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Active, not recruiting | 6 |
| Recruiting | 6 |
| Terminated | 4 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 5 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 5 |
| Vastra Gotaland Region | 2 |
| AbbVie | 1 |
| Astex Pharmaceuticals, Inc. | 1 |
| Boehringer Ingelheim | 1 |
| Celgene | 1 |
| Eli Lilly and Company | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Exscientia AI Limited | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 28 |
| Myelodysplastic Syndromes | 7 |
| Leukemia, Myelomonocytic, Chronic | 4 |
| Recurrence | 4 |
| Leukemia | 3 |
| Lymphoma, Non-Hodgkin | 2 |
| Multiple Myeloma | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Blast Crisis | 1 |
| Bone Marrow Diseases | 1 |
Trials
Showing 26 to 28 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.